MedTrace Logo

Impact of Cannabinoids on Menopause Symptoms

NCT06831916 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-04-04

No results posted yet for this study

Summary

The purpose of the study is to examine the impact of the hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.

Conditions

Interventions

DIETARY_SUPPLEMENT

Active Cannabinoid Product

Participants will be administered a product with minor cannabinoids and terpenes.

OTHER

Placebo

Participants will be administered a placebo.

Sponsors & Collaborators

  • Terra Mater Botanicals Pty Ltd

    collaborator UNKNOWN

  • Washington State University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-03
Primary Completion
2027-01-12
Completion
2027-01-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06831916 on ClinicalTrials.gov